Drugs / PIPE-505
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04462198 | Oct 2020 → Jun 2021 | sensorineural hearing loss disorder | Contineum Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIPE-505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04462198 ↗ |
| Route | Other | “Intratympanic injection” NCT04462198 ↗ |